Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 23;62(3):e02397-17.
doi: 10.1128/AAC.02397-17. Print 2018 Mar.

Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers

Helio S Sader  1 , Rodrigo E Mendes  2 , Leonard R Duncan  2 , Michael A Pfaller  2 , Robert K Flamm  2
Affiliations

Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers

Helio S Sader et al. Antimicrob Agents Chemother. .

Abstract

Dalbavancin activity was assessed against a large collection of Staphylococcus aureus isolates (n = 59,903), including isolates with decreased susceptibility to vancomycin (MIC, ≥2 mg/liter; n = 1,141), daptomycin (MIC, ≥2 mg/liter; n = 48), telavancin (MIC, ≥0.12 mg/liter; n = 52), teicoplanin (MIC, ≥4 mg/liter; n = 143), and/or linezolid (MIC, ≥8 mg/liter; n = 25). Dalbavancin displayed susceptibility rates ranging from 90.4% (isolates with telavancin MIC ≥0.12 mg/liter) to 100.0% (linezolid-resistant isolates) and lower MIC values than the comparators against these resistant subsets.

Keywords: glycopeptides; lipoglycopeptides; vancomycin-intermediate S. aureus.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Summary of dalbavancin activity when tested against S. aureus isolates with decreased susceptibility to glycopeptides, daptomycin, and/or linezolid from U.S. medical centers. Abbreviations: VAN ≥2, isolates with vancomycin MICs of ≥2 mg/liter; DAPTO-NS, daptomycin nonsusceptible (MIC, ≥2 mg/liter); TLV ≥0.12 mg/liter, isolates with telavancin MICs of ≥0.12 mg/liter; TEICO ≥4, isolates with teicoplanin MICs of ≥4 mg/liter; LNZ-R, linezolid resistant.
See this image and copyright information in PMC

References

    1. Bal AM, David MZ, Garau J, Gottlieb T, Mazzei T, Scaglione F, Tattevin P, Gould IM. 2017. Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: an in-depth review of newer antibiotics active against an enduring pathogen. J Glob Antimicrob Resist 10:295–303. doi: 10.1016/j.jgar.2017.05.019. - DOI - PubMed
    1. Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, Edwards JR, Sievert DM. 2016. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol 37:1288–1301. doi: 10.1017/ice.2016.174. - DOI - PMC - PubMed
    1. Sader HS, Mendes RE, Streit JM, Flamm RK. 2017. Antimicrobial susceptibility trends among Staphylococcus aureus from U.S. hospitals: results from 7 years of the ceftaroline (AWARE) surveillance program, 2010 to 2016. Antimicrob Agents Chemother 61:e01043. doi: 10.1128/AAC.01043-17. - DOI - PMC - PubMed
    1. van Hal SJ, Lodise TP, Paterson DL. 2012. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 54:755–771. doi: 10.1093/cid/cir935. - DOI - PubMed
    1. Kalil AC, Van Schooneveld TC, Fey PD, Rupp ME. 2014. Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis. JAMA 312:1552–1564. doi: 10.1001/jama.2014.6364. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources